A detailed history of Somerville Kurt F transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Somerville Kurt F holds 22,643 shares of VRTX stock, worth $9.83 Million. This represents 1.49% of its overall portfolio holdings.

Number of Shares
22,643
Previous 23,186 2.34%
Holding current value
$9.83 Million
Previous $10.3 Million 14.1%
% of portfolio
1.49%
Previous 1.78%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 07, 2025

SELL
$366.54 - $479.53 $199,031 - $260,384
-543 Reduced 2.34%
22,643 $8.87 Million
Q2 2025

Jul 23, 2025

BUY
$421.16 - $509.5 $130,559 - $157,945
310 Added 1.36%
23,186 $10.3 Million
Q1 2025

May 06, 2025

BUY
$402.49 - $513.76 $999,785 - $1.28 Million
2,484 Added 12.18%
22,876 $11.1 Million
Q4 2024

Feb 12, 2025

BUY
$396.64 - $516.74 $1.49 Million - $1.94 Million
3,748 Added 22.52%
20,392 $8.21 Million
Q3 2024

Nov 12, 2024

BUY
$460.0 - $505.78 $2.09 Million - $2.3 Million
4,546 Added 37.58%
16,644 $7.74 Million
Q2 2024

Aug 12, 2024

BUY
$392.81 - $485.53 $2.87 Million - $3.54 Million
7,300 Added 152.15%
12,098 $5.67 Million
Q1 2024

May 13, 2024

BUY
$407.69 - $446.08 $1.07 Million - $1.17 Million
2,623 Added 120.6%
4,798 $2.01 Million
Q4 2023

Feb 13, 2024

BUY
$343.0 - $410.68 $257,250 - $308,010
750 Added 52.63%
2,175 $884,000
Q3 2023

Nov 13, 2023

SELL
$338.18 - $362.46 $25,363 - $27,184
-75 Reduced 5.0%
1,425 $495,000
Q3 2020

Oct 28, 2020

SELL
$255.65 - $303.1 $10,226 - $12,124
-40 Reduced 2.6%
1,500 $408,000
Q2 2020

Jul 28, 2020

SELL
$225.48 - $295.8 $1,803 - $2,366
-8 Reduced 0.52%
1,540 $447,000
Q3 2017

Oct 26, 2017

BUY
$148.13 - $162.24 $229,305 - $251,147
1,548
1,548 $235,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $111B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Somerville Kurt F Portfolio

Follow Somerville Kurt F and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Somerville Kurt F, based on Form 13F filings with the SEC.

News

Stay updated on Somerville Kurt F with notifications on news.